

Growth Phase-Dependent Regulation and Membrane Localization of SpaB, a Protein Involved in Biosynthesis of the Lantibiotic Subtilin

Z. GUTOWSKI-ECKEL, C. KLEIN, K. SIEGERS, K. BOHM, M. HAMMELMANN,
AND K.-D. ENTIAN*

*Institute for Microbiology, Biozentrum der Johann Wolfgang Goethe-Universität,
Marie-Curie-Strasse 9, W-60439 Frankfurt/Main, Federal Republic of Germany*

Received 15 July 1993/Accepted 15 September 1993

The information responsible for biosynthesis of the lantibiotic subtilin is organized in an operon-like structure that starts with the *spaB* gene. The *spaB* gene encodes an open reading frame consisting of 1,030 amino acid residues, and it was calculated that a protein having a theoretical molecular mass of 120.5 kDa could be produced from this gene. This is consistent with the apparent molecular weight for SpaB of 115,000 which was estimated after sodium dodecyl sulfate-gel electrophoresis and identification with SpaB-specific antibodies. The SpaB protein is very similar to proteins EpiB and NisB, which were identified previously as being involved in epidermin and nisin biosynthesis. Upstream from SpaB a characteristic sigma A promoter sequence was identified. An immunoblot analysis revealed that SpaB expression was strongly regulated. No SpaB protein was detected in the early logarithmic growth phase, and maximum SpaB expression was observed in the early stationary growth phase. The expression of SpaB was strongly correlated with subtilin biosynthesis. Deletion mutations in either of two recently identified regulatory genes, *spaR* and *spaK*, which act as a "two-component" regulatory system necessary for growth phase-dependent induction of subtilin biosynthesis (C. Klein, C. Kaletta, and K. D. Entian, *Appl. Environ. Microbiol.* 59:296-303, 1993), also resulted in failure of SpaB expression. To investigate the intracellular localization of SpaB, vesicles of *Bacillus subtilis* were prepared. The SpaB protein cosedimented with the vesicle fraction and was released only after vigorous resuspension of the vesicles. Our results suggest that SpaB is membrane associated and that subtilin biosynthesis occurs at the cytoplasmic membrane of *B. subtilis*.

Lantibiotics are peptide-derived antibiotics that exhibit high levels of antimicrobial activity against several pathogenic gram-positive bacteria, such as *Propionibacterium acnes*, staphylococci, streptococci, and clostridia. They contain the unusual amino acids meso-lanthionine, dehydroalanine, and dehydrobutyrine (49). Lantibiotics can be divided into two subgroups (21): (i) the linear lantibiotics, including nisin (38, 39, 42), subtilin (17), epidermin (1, 2), gallidermin (26), mersacidin (15, 33), and Pep5 (43), and (ii) the globular lantibiotics, including cinnamycin (= Ro09-0198 = lanthiopeptin) (6, 14, 27, 28, 41), duramycin (16), and ancovenin (52). The most important linear lantibiotics are nisin from *Lactococcus lactis*, subtilin from *Bacillus subtilis*, epidermin from *Staphylococcus epidermidis*, and gallidermin from *Staphylococcus gallinarum*.

Epidermin and gallidermin are used in the treatment of acne because of their high levels of activity against *P. acnes*. Subtilin and nisin are very similar to each other and have the same arrangement of lanthionine bridges. Nisin is used as a food preservative because it is very effective against certain gram-positive bacteria such as staphylococci, streptococci, and clostridia (38, 39, 42). The potent bactericidal activities of nisin and other linear lantibiotics are based on depolarization of energized bacterial cytoplasmic membranes (21).

The main difficulties in exploiting lantibiotics commercially are the low production rates of these compounds. To overcome these problems, the biosynthesis of lantibiotics

has to be elucidated. Compared with other lantibiotic-producing organisms, the subtilin-producing strains of *B. subtilis* are much more suitable for genetic analysis. Therefore, we chose *B. subtilis* as a model organism to investigate lantibiotic biosynthesis.

The ribosomal origin of lantibiotics was first shown by the isolation of the epidermin structural gene, *epiA* (49). The general structure of lantibiotic genes is the same for all lantibiotics described thus far. The primary transcript of the gene for each linear lantibiotic encodes a prepeptide which consists of an N-terminal leader sequence followed by the C-terminal propeptide from which the lantibiotic matures and a characteristic proteolytic processing site with proline at position -2. This gene structure has been found for subtilin (5), nisin (8, 12, 22), gallidermin (48), Pep5 (24), and cinnamycin (23), a globular lantibiotic.

On the basis of the results of Ingram (19, 20) and the epidermin prepeptide sequence, we proposed that the leader sequence has an important function during lantibiotic maturation and that a dehydration reaction occurs at serine and threonine residues and subsequently sulfur is added from cysteine (49). This hypothesis was supported by the isolation of prepeptides containing dehydroalanine (53).

Several genes have been identified as essential for the synthesis of the lantibiotics subtilin, epidermin, and nisin. A sequence analysis of DNA fragments adjacent to *spaS* revealed two complete open reading frames, *spaC* and *spaT*, and the C-terminal fragment of a third open reading frame, *spaB* (25, 31). Gene deletions within *spaB* and *spaC* created subtilin-negative mutants, which proved that the proteins encoded by these genes are essential for subtilin biosynthe-

* Corresponding author. Mailing address: Institute for Microbiology, J. W. Goethe University, Marie-Curie-Strasse 9, D-60439 Frankfurt/Main, Germany. Phone: 69/5800 9526. Fax: 69/5800 9527.

sis (25, 31). For epidermin five open reading frames, *epiB*, *epiC*, *epiD*, *epiP*, and *epiQ*, were identified adjacent to the *epiA* structural gene (46, 47). These genes supported heterologous epidermin biosynthesis in *Staphylococcus carnosus*, which proved that they are sufficient for epidermin synthesis in this host (46, 47). In addition, epidermin biosynthesis mutants could be complemented by using these genes (3, 4). For nisin biosynthesis three open reading frames, *nisB*, *nisT*, and *nisC*, were identified near the *nisA* structural gene (13). Genes *epiB* and *epiC* were homologous to *spaB* and *spaC*, respectively, and to *nisB* and *nisC*, respectively, indicating that the proteins encoded by these genes have been conserved and may have a major function in lantibiotic biosynthesis.

Isolation of the complete open reading frame of *spaB* and preliminary characterization of the protein that it encodes, SpaB, are described in this report. Our results confirm that SpaB is essential for subtilin biosynthesis and support our previous hypothesis that lantibiotic biosynthesis occurs at the cell membrane (49).

MATERIALS AND METHODS

Strains and media. *B. subtilis* ATCC 6633 was used as the subtilin-producing strain. Recombinant plasmids were amplified in *Escherichia coli* RR1 (F^- *hsd520 supE44 ara-14 proA2 lacY1 galK2 rpsL20 xyl-5 mtl-1*). *E. coli* strains transformed with plasmid pATH were grown in M9 medium (44) supplemented with 0.5% Casamino Acids and 40 μ g of ampicillin per ml or in M9 medium supplemented with 0.5% Casamino Acids, 20 μ g of tryptophan per ml, and 40 μ g of ampicillin per ml.

Micrococcus luteus ATCC 9341 was used as a test strain in subtilin assays. *E. coli* and *M. luteus* were grown on Luria-Bertani medium (GIBCO, Neu-Isenburg, Germany). *B. subtilis* was grown on TY medium (0.8% tryptone, 0.5% yeast extract [Difco Laboratories, Detroit, Mich.], 0.5% NaCl). When resistance markers were used, 10 μ g of kanamycin per ml and 5 μ g chloramphenicol per ml were added to the medium.

Molecular biology techniques. We used previously described protocols for molecular biology techniques (44). DNA was cleaved by using the conditions recommended by the supplier of the restriction enzymes (Boehringer GmbH, Mannheim, Germany). Restriction endonuclease-digested DNA was eluted from 0.7% agarose gels by the freeze-squeeze method (50).

Plasmid isolation. The procedure of Birnboim and Doly (7) was used to isolate the plasmids of *E. coli*. When necessary, the plasmids were purified by centrifugation for 12 h at 80,000 rpm with a Beckman model TL 100 ultramicrocentrifuge and a model TLA 100.2 rotor.

For Southern hybridization double-stranded DNA fragments were labeled by nick translation by using [α - 32 P]ATP and DNA polymerase I (Boehringer), as described by Sambrook et al. (44). For DNA sequencing, both strands of DNA were sequenced by the radioactive chain termination method by using T7 DNA polymerase (Pharmacia, Freiburg, Germany) and appropriate primers (45).

Subtilin bioassay. Test strain *M. luteus* ATCC 9341 was grown to an A_{578} of 0.8, and 0.3 ml of this culture was added to 500 ml of molten Luria-Bertani agar; this preparation was mixed, and 10-ml portions were poured into petri dishes. *B. subtilis* was spread onto each agar surface, and the diameter of *M. luteus* growth inhibition around each colony was determined.




FIG. 1. Genetic analysis of *B. subtilis* DNA adjacent to *spaS*. Cloning and sequencing of plasmid pCK38 have been described recently (31). For a description of the isolation of fragments pKB2 and pCE42, see Results. Abbreviations: XI, *Xba*I; PI, *Pst*I; EV, *EcoRV*; SI, *Sac*I; HIII, *Hind*III.

Isolation of *B. subtilis* membrane vesicles. *B. subtilis* membrane vesicles were prepared by using a modification of the method previously described by Konings et al. (34). Cells (4 g, wet weight) were suspended in 1 liter of 0.05 M potassium phosphate (pH 8.0) containing 2 mM phenylmethylsulfonyl fluoride. Incubation was stopped by centrifuging the preparation at $48,000 \times g$ for 30 min at 4°C, and the membranes were suspended by using a Potter-Elvehjem homogenizer in 0.1 M potassium phosphate buffer (pH 6.6) containing 10 mM sodium EDTA. After further centrifugation at $48,000 \times g$ for 30 min at 4°C, the pellet containing the purified membrane vesicles was resuspended in 0.1 M potassium phosphate buffer (pH 6.6) containing 10 mM sodium EDTA, and aliquots (0.5 ml) were rapidly frozen and stored in liquid nitrogen. Protein was determined by the microbiuret method (54).

To test the integrity of the isolated membrane vesicles, the same procedure was performed in the presence of 100 mM 8-hydroxy-1,3,6-pyrenetrisulfonate (pyranine), a dye which has been proven not to interact with membranes. After the final centrifugation step the membranes were carefully suspended by using a Potter-Elvehjem homogenizer in 0.1 M potassium phosphate buffer (pH 6.6) containing 10 mM sodium EDTA. The vesicles containing pyranine were separated from the external pyranine on a Dowex 1x8 column (50/100 mesh; Serva, Heidelberg, Germany) (11). A 100- μ l solution containing vesicles was diluted with 900 μ l of 0.1 M potassium phosphate buffer (pH 10) containing 1% Triton X-100 to make the vesicles leaky, and fluorescence was measured at 450 nm.

TrpE fusion protein and antibody isolation. The 1.4-kB *EcoRV-Hind*III fragment (Fig. 1) corresponding to the C-terminal fragment (425 amino acids) of SpaB was cloned into vector pATH2 (32). For expression of the fusion protein, the plasmid was transformed into *E. coli* RR1. Cells containing the pATH vector for expression of TrpE fusion proteins were grown overnight in M9 medium containing 0.5% Casamino Acids, 20 μ g of tryptophan per ml, and 40 μ g of ampicillin per ml, diluted 1:10 in M9 medium containing 0.5% Casamino Acids and 40 μ g of ampicillin per ml, and grown for 2 h at 30°C. Indoleacrylic acid was added to a final concentration of 2 μ g/ml, and the culture was grown at 30°C for 4 h. The cells were harvested by centrifugation and lysed by adding sodium dodecyl sulfate (SDS) sample buffer (100 mM NaPO₄ [pH 7.0], 5% β -mercaptoethanol, 4% SDS, 8 M

urea, 0.02% bromphenol blue). The fusion protein was purified by loading 10 to 20 mg of protein onto a preparative SDS-polyacrylamide gel electrophoresis (PAGE) gel.

To prepare antibodies, bands corresponding to the fusion protein were cut from SDS-polyacrylamide gels and isolated by electroelution. The purified fusion protein was suspended in an equal volume of ABMI or ABMIII adjuvant (Sebak, Aidenbach, Germany). The mixture was injected subcutaneously into rabbits. The initial injections contained 250 to 350 μ g of the fusion protein. Secondary injections (after 4 weeks) and later booster injections (every 2 weeks) contained approximately 250 μ g of the fusion proteins. Serum was collected and tested 2 weeks after each booster injection. The final antisera were collected after two booster injections. The specificities of the antisera were determined by a Western blot (immunoblot) analysis by comparison with preimmunization sera.

SDS-gel electrophoresis and Western blot analysis. SDS-PAGE was performed with a Mini-PROTEIN II dual slab cell apparatus by using the discontinuous system and 7.5% acrylamide separation gels (37). Proteins were electrotransferred onto nitrocellulose paper (pore size, 0.45 μ m; Schleicher & Schuell, Dassel, Germany) by using a discontinuous buffer system (model LKB 2117 Multiphor II electrophoresis system; Pharmacia-LKB, Freiburg, Germany) as recommended by the supplier. Protein was estimated by the microbiuret method (54).

After protein adsorption the nitrocellulose membranes were stained with India ink (Pelikan AG, Hannover, Germany) (18). The stain was prepared as a 0.1% (vol/vol) solution in phosphate-buffered saline (PBS) (pH 7.4) containing 1% acetic acid and 0.05% Tween 20. The nitrocellulose sheets were stained for 15 min at room temperature with shaking on a rotary shaker and then incubated in PBS containing 20% fetal calf serum (GG-free; GIBCO BRL, Berlin, Germany) for 10 min. Antibody-containing sera were diluted 1:1,000 with 20% fetal calf serum. The nitrocellulose membranes were exposed to diluted antibody solutions for 6 h or overnight on a rotary shaker, and washed three times at room temperature for 10 min with TBST (10 mM Tris, 150 mM NaCl, 0.05% Triton X-100; pH 8.0), and then incubated with an appropriate solution containing anti-rabbit immunoglobulin G (alkaline phosphatase conjugate; Sigma, Munich, Germany) in TBST for 2 h. Finally, the membranes were washed three times with TBST.

Processed nitrocellulose membranes were washed with AP buffer (100 mM Tris, 100 mM NaCl, 5 mM $MgCl_2$; pH 9.5) and exposed to AP buffer containing nitroblue tetrazolium and 5-bromo-4-chloro-3-indolylphosphate. Bands that reacted positively became visible as brown bands within 5 to 10 min. Finally, the membranes were thoroughly rinsed with H_2O .

Nucleotide sequence accession numbers. The data bank nucleotide sequence accession numbers for proteins NisB and EpiB are X68307 and X62386, respectively. The sequence data determined in this study have been deposited in the GenBank data base under accession number L24075.

RESULTS

Isolation and nucleotide sequence of *spaB*. Previously, we described the isolation of a 4.9-kb *XbaI* fragment (pCK38) that contained the subtilin structural gene (*spaS*), genes *spaC*, *spaB*, and *spaT*, and the 5' part of the *spaB* gene. All five genes were involved in subtilin biosynthesis, as shown by the failure of gene disruption mutants to synthesize

subtilin (31). By using the 4.9-kb *XbaI* fragment, adjacent restriction sites were determined by a Southern blot analysis, and a 2.7-kb *EcoRV-PstI* fragment that overlapped the 4.9-kb *XbaI* fragment was isolated by hybridization with the labeled *XbaI* fragment (plasmid pKB2). To obtain the complete *spaB* gene, an additional overlapping 1.8-kb *SacI-HindIII* fragment was cloned by the same procedure by using the labeled 2.7-kb fragment as a hybridization fragment, yielding plasmid pCE42 (Fig. 1).

A protein containing 1,030 amino acids was derived from the *spaB* gene; this protein had a predicted molecular mass of 1,205 kDa (Fig. 2). The *spaB* gene is preceded by a Shine-Dalgarno sequence at an appropriate distance, and its putative promoter is similar to vegetative sigma A promoters of *B. subtilis* (40).

Homology of SpaB to NisB and EpiB. SpaB was found to be homologous to proteins NisB (13) and EpiB (47) which are encoded by genes located adjacent to the structural genes of the lantibiotics nisin and epidermin. SpaB was 28.1% homologous to NisB over the entire protein and 24.5% homologous to EpiB (Fig. 3).

No additional homologies with previously described proteins were found for SpaB, NisB, and EpiB in data bases (the GenBank, EMBL, Protein Identification Resource, and Swiss-Prot data bases were examined in August 1992, September 1992, June 1992, and August 1992, respectively). According to our genetic data proteins SpaB (as well as NisB and EpiB) and SpaC (as well as NisC and EpiC) should be involved in lanthionine formation. We hypothesize that these proteins may correspond to dehydratases responsible for dehydration of serine and threonine residues and to lanthionine synthases that catalyze the addition of cysteine sulfur to the double bonds of dehydroalanine and dehydrobutyrine. Within the N-terminal parts of SpaB, NisB, and EpiB an experiment to determine levels of similarity between SpaB, NisB, or EpiB and threonine dehydratases IlvA (37) and Tdc (29) from *E. coli* revealed that there was 31% similarity over a 60-amino-acid residue region for NisB (amino acids 203 to 263 of NisB compared with amino acids 248 to 306 of *E. coli* IlvA) and 18.3% similarity over a 126-amino-acid residue region for SpaB (amino acids 172 to 294 of SpaB compared with amino acids 206 to 329 of *E. coli* IlvA/Tdc).

Within the C-terminal parts of SpaB, NisB, and EpiB there was 21% similarity for NisB over a 157-amino-acid residue region (amino acids 720 to 867 of NisB compared with amino acids 305 to 462 of *E. coli* IlvA) and 22% similarity over a 100-amino-acid residue region for EpiB (amino acids 828 to 928 of EpiB compared with amino acids 346 to 437 of *E. coli* Tdc/IlvA). Although these levels of similarity are low, they suggest that SpaB, NisB, and EpiB play a role in dehydration during lantibiotic biosynthesis.

In addition to sequence homology levels, hydrophobicity plots also revealed high levels of similarity among the three proteins because a characteristic change from a slightly hydrophobic peak to a strongly hydrophilic peak was observed (Fig. 4). However, we predicted that there should be a hydrophobic area in the C-terminal region. A computer analysis in which the method of Chou and Fasman (9) was used revealed that all three proteins may have similar secondary structures. A comparison of the predictions for α -helices and β -sheets revealed 14 α -helices and 20 β -sheets that were common to all three proteins (Fig. 3).

Identification of the *spaB* gene product. The *spaB* gene product has been implicated in posttranslational modification of the subtilin prepeptide. In order to identify and

SacI 10 20 30 40 50 60 70 80 90 100
GAGCTCCGCTCGCGCTTCTGTCTATTATGGCAGGCTTGCACGCGCTCTCGTCATTGCCATCGGAATTACAGCAATCGGCACATTTGTTCGGCGCCGGGG
 110 120 130 140 150 160 170 180 190 200
 GGCTCGGGGATATGATTGTCCGCGGCTCAAACGCGACAACGGAACTGCGATTATTCTCGCAGGCGCGACCCCGACTGCGGTAATGGCCATAGGAGCAGA
 210 220 230 240 250 260 270 280 290 300
 TTTGATAATGGCCTGGATTGAAAGGTTCTTGAATCCGGTGAACAAAAAGCAGAAGAAAGGTAATAAGTGTATAGAGTTAAGCAAAAAGGATTCTTTTC
 310 320 330 340 "-35 Box" 360 "-10 Box" 390 400
 TGAGAGGGAAAAGAGTCTTTTTTTATGGTATTTACTGGGTGGATCTTGATATTTTTTTGATTTTTAGAAATGTATAGTAAAAATAGAGTATTGTAATAT
 410 420 430 440 450 460 470 S/D 490 500
 TTTGGTTCAAATAGAATAATATGGAGGACTAAGCAGAGGGATGTAGAATTGTTTTTATTAAGAAGCGGATAAATATGGGGGGCTATAGACTAATATGAAA
SpaB> M K
 510 520 530 540 550 560 *EcoRI* *EcoRV* 590 600
 TCCTTATATACACCTACAGATTATTATATGATTTCGGGTTCTTTAGTACATCAAGACTTAAAAATGAGAATTCTCAGGATATCGATCAGTTATTACATG
 S L Y T P T D Y Y M I R V P L V H Q D L K N E N S Q D I D Q L L H D
 610 620 630 640 650 660 670 680 690 700
 ACCTTTGCAACGATTCTATTATTTTCGGGAACAAATACTGGTATCTAGCAGGACACTATATGAAACAATACATACTTTCTGCAAGCGCCGGATAAATTTAA
 L C N D S L F R E Q I L V S S R T L Y E T I H T F L Q A P D K L K
 710 720 730 740 750 760 770 780 790 800
 AGGGAAAAAAGCGCAACTTTCAACAGGCTATTTTGAAGTATGCAACAAGAAGAGCAACAAGAACCACACCTTTTGGCCTTTTTCTTCAGTCGGTATA
 G K K K R N F Q Q A I L K Y A T R R A T R T T P F G L F S S V G I
 810 820 830 840 850 860 870 880 890 900
 GGGTCGTTTTCTGATAAAAATCACTTATCTTTTAAATCAACATTCATTTTACAAAAGGCTCGTGTGATTGGAGTGGCTCTACCAATTAATTAGAAAAT
 G S F S D K N H L S F N Q H S F Y K K A R V D L E W L Y Q L I R K L
 910 920 930 940 950 960 970 980 990 1000
 TGGAAAACGAATACACCGACCGACTTTCTTTTACATTAATTCGGCTTGTATATTAAGGGTGACCGGGCTTACTTGTGTACAGCACAGATGGAAAATC
 E N E Y T D R L S F T L N S A C Y I K G D R A Y L L Y S T D G K S
 1010 1020 1030 1040 1050 1060 1070 1080 1090 1100
 TGAAGAAGTTAGTGTTCGTGCGACATCTGTTTTCTATTGATAAATGAACTGTGTGGTGAATCTGCTGCATATCAAGATATAATCCGTTGTTTGATAGAT
 E E V S V R A T S V F Y L I N E L C G E S A A Y Q D I I R C L I D
 1110 1120 1130 1140 1150 1160 1170 1180 1190 1200
 AACTATCCAAATACTCCAATAAATAAATAAATTAATCAGTACGTAGCAGACCTTATTGACAAAGAGTTCCCTTATATCAAACCTTACGGCCCGCATGACTGTTT
 N Y P N T P I N K I N Q Y V A D L I D K E F L I S N L R P P M T V S
 1210 1220 1230 1240 1250 1260 1270 1280 1290 1300
 CAGATCAATTTAGTATTAATTGATCAAGCGGAAAGCCGCCATATCCAAATGAACTCATTAGGCTTGTAAAGACATTCAATATCAGATAGATGCATA
 D Q F Q Y L I D Q A E S R H I P N E L I Q A C K D I Q Y Q I D A Y
 1310 1320 1330 1340 1350 1360 1370 1380 1390 1400
 TAATCGGATCACTATCGGAGAGGGAGAGCATCAGTATTTAAATCTGATTGAAACAATGAATAAACTCATAAAGGCATCATCTCCTCTGCAAGTAGACGCT
 N R I T I G E G E H Q Y L N L I E T M N K L I K A S S P L Q V D A
 1410 1420 1430 1440 1450 1460 1470 1480 1490 1500
 GGGCTGGCAGACTCCTCCATTCATTAATAGATAATGAAACATCTCTCGCCATAAGTGAATTGGCAAGCATGTTTACTTATATGGCTTCTCCCTCTGCCAATA
 G L A D S S I Q L D N E T S L A I S E L A S M F T Y M A S P S A N T
 1510 1520 1530 1540 1550 1560 1570 1580 1590 1600
 CATTAGACCCTTGAAAAATACCACAATGTATTTTTGGAACGCTATGGATATGAAAGAGAAGTTCTCTCTAGAAATGCTATGTTCCAGCACTGGCAT
 L D H L E K Y H N V F L E R Y G Y E R E V P L L E M L C S S T G I
 1610 1620 1630 *EcoRI* 1650 1660 1670 1680 1690 1700
 TGGTGCTCCTGCTACGTACCGAATCCTGCTAATGAATCTTTGAAGAAACATCATTTGGGGAGCAATTTTACCAGGAAATGAAACAATTTTTCATGAGA
 G A P A T Y T N P A N E F F E E T S F G E Q F S P E M K Q F F M R
 1710 1720 1730 1740 1750 1760 1770 1780 1790 1800
 AAGTATTTGAATCAGTTAGAAAAGAAAGCTCCTATTCAATTAGACGACGAAACATTCATAGAATTTGCAACTCTGAAATTGCTGATGAGGAAATCCAT
 K Y F E S V R K K A P I Q L D D E T F H R I C N S E I A D E E I P L
 1810 1820 1830 1840 *HindIII* 1860 1870 1880 1890 1900
 TATCATTTGAACTCAATTTCTTTGTTAAATACGAAATGGGAGAGTTAAGCTTTATTTAGCCCCAACGTCGGATCTACCCGCGCAGGGAAAACATTTGG
 S F E L N F F V K L R N G R V K L Y L G P N V G S T R A G K T F G

FIG. 2. Nucleotide sequence of the subcloned fragments of pCE42, pKB2, and pCK38 containing the *spaB* reading frame and its promoter region. The putative promoter site and the Shine-Dalgarno sequence (S/D) are underlined.

1910 1920 1930 1940 1950 1960 1970 1980 1990 2000
GAGATTTTCTCATATGTCTGATTCAATCAGTCAAATCATAAAGACCTTACATAACAAGGAGAAAGAGTTAACAGAGTGTAAACGAAAGTTTGTGAAGT
R F S H M S D S I S E I I K T L H N K E K E L T E C N T K V C E L
2010 2020 2030 2040 2050 2060 2070 2080 2090 2100
AGTATTGTGCCTAATCAAAGTAGGCTGGAAATGTAACAAGAAATGTAAGCTACCGAGAAAAAGAGATGTCTCTTTTTACGAACAGTGTCTGCATCTCA
S I V P N Q T R S G N V T R N V S Y R E K E M S L F T N S A L H L N
2110 2120 2130 2140 2150 2160 2170 2180 2190 2200
ATGATTCCGTCAAAGCTGAAGATATTCTAATTGGAATCAATAAAGACCATAACTTTTATGCTAGACATAAAACAAGTGGCGAAATTTCTGTCTTTTGTGAGTC
D S V K A E D I L I G I N K D H N F Y A R H K T T G E I L S F E S
2210 2220 2230 2240 2250 2260 2270 2280 2290 2300
AAATCATATGTTTAACTTTTATTAATGACCAACGCTGTACGGTTTTTATTAGAGATTTCAAGAGATGGTAAAAGAAAAATGGAATGATTTCCCGTGGTTTT
N H M F N P L L M T N A V R F L L E I S R D G K R K W N D F P W F
2310 2320 2330 2340 2350 2360 2370 2380 2390 2400
AGTATCTATAGTGATTTCAAGTATATTCCTGAAATCAAATATAAAGAGATAACCTTATCTTGTGAACAATGGCTGATATACAAAATGATTTAAGCATGC
S I Y S D F K Y I P E I K Y K E I T L S C E Q W L I Y K N D L S M H
2410 *Xba*I 2430 2440 2450 2460 2470 2480 2490 2500
ACTCGAATGCATCTCTAGAAAGATAAAAATCTCCTTTTTTTGAATTTTCATCGTACTTATGAACTGCCGCAAACATTTTATATCGTTAACGCAGACAATCG
S N A S L E E I K S P F F E F H R T Y E L P Q T F Y I V N A D N R
2510 2520 2530 2540 2550 2560 2570 2580 2590 2600
ATTATTGATTGATATAGAGAATGATTGTACTTTGGATGTTTTTTCTGGGAATTGAAAAAACAACCATACCAGCCATTACAACCTTGTGGCTGTTGAG
L L I D I E N D C T L D V F F W E L K K T N H N Q P L Q L V A V E H
2610 2620 2630 2640 2650 2660 2670 2680 2690 2700
CATGATGCAGATGCGTTAATGGATAGAAAACAAAATGACTATTCCGGGAGAAATCGTCGTTCCGCTGCTTAGAAAACAACAGAAAAACCATTTGATTTAC
D A D A L M D R N Q N D Y S G E I V V P L L R K Q P E K P L Y L P
2710 2720 2730 2740 2750 2760 2770 *Hind*III 2790 2800
CGGTTCTTAACGCAATAGAGGGAAGTGGTCCGACAGAATAAAAATGCCATTTGAAGACTGGCTGTTTATTAAGCTTTATTGTAACAACAAGAGAAGA
V L N A I E G S G S D R I K M P F E D W L F I K L Y C K Q T R E E
2810 2820 2830 2840 2850 2860 2870 2880 2890 2900
AGAGCTAATGCTTTTGAATAGCGGATTTTTATAACCAGATTTCTGATCAATATCCAGTCAGACATTTCTTTATGAGGTATCGGGATCCAAAGCCTCAT
E L I A F E I A D F Y N Q I S D Q Y P V R H F F M R Y R D P K P H
2910 2920 2930 2940 2950 2960 2970 2980 2990 3000
ATAAGACTTAGATTTAATGGAAGCCGAAGTGTGTACAGCTTGTTCCTCCCAATTATTGAATGGCTGAAAAGCTTAAGAGAAAAAGGACTGGTTTCAG
I R L R F N G K A E V L Y S L F P Q L L N W L K S L R E K G L V S E
3010 3020 3030 3040 3050 3060 3070 3080 3090 3100
AGTCTGTTATCACTCAATACGAGCGGGAGATAGAACGATATGGCGGGCTAAGCCTTATGGAGGCTGCAGAACAGCTTTTCTGTGAAGACAGCAAAGTTGT
S V I T Q Y E R E I E R Y G G L S L M E A A E Q L F C E D S K V V
3110 3120 3130 3140 3150 3160 3170 3180 3190 3200
TGAAATGATGATTAGAATGCACCGGATGAAAGATATTACGATAAGCAAGGAAATTCAGGCATGGTTTCGGTTATACAGTTTTTAGAACAGTTCGAGCTA
E M M I R M H R M K D I T I S K E I A G M V S V I Q F L E Q F E L
3210 3220 3230 3240 3250 3260 3270 3280 3290 3300
ACGTTTGAAGAACAGTTAACTTTTTTAGAGAGAAATTCCTTACAGAATGAGTATCGTACTGAATTTAAAAGGATAGAGAAATGTATATTGAAATATGCA
T F E E Q L T F L E R N S L Q N E Y R T E F K K D R E M Y I E I C N
3310 3320 3330 3340 3350 3360 3370 3380 3390 3400
ATTCTGACAGAGATTTGGGATAATCTCAAGAAAACAAGTGTGGCGGTATGTTATATGAACTTTGAAAACAAGAAAAATGGCTGCAGCTCATTATGCATT
S D R D W D N L K K T S D G G M L Y E T L K T R K M A A A H Y A F
3410 3420 3430 3440 3450 3460 3470 3480 3490 3500
TTTAAATCAAAAAGGCATTTGATAACAAAGATGAAGTTTATTCACGTATAGGAAGTATCATCCATCTGCATTGCAATCGTTTATTCGGAACCGACAGAGAA
L I K K A F D N K D E V Y S R I G S I I H L H C N R L F G T D R E
3510 3520 3530 3540 3550 3560 3570 3580 3590 3600
CTGGAAAATAAAATCTCACCTATGCAGACATTTCTTATATGCGCAACGATATCAAAGATGAATGGTAGTTTAGCATGGAAGTAAAGGAACAACACTGAA
L E N K I L T L C R H S L Y A Q R Y Q K M N G S L A W K

FIG. 2—Continued.




FIG. 3. Sequences and predicted secondary structures of proteins SpaB, NisB, and EpiB. Similar amino acid residues are indicated by dots, and identical amino acid residues are indicated by colons. The arrows indicate areas where β -sheets are predicted, and the rods indicate areas having an α -helical character. Predictions were made by using the method of Chou and Fasman (9) and "Prosis" (Hitachi).

characterize this protein, polyclonal antibodies were obtained by immunizing rabbits with a TrpE-SpaB fusion protein expressed in *E. coli*. The protein was manufactured by fusing the *spaB* open reading frame (425 amino acid

residues of the C-terminal part) to the *trpE* open reading frame of *E. coli*. The antibodies obtained cross-reacted with a protein having a molecular mass of approximately 115 kDa after SDS-gel electrophoresis (Fig. 5).






FIG. 3—Continued.

Neither signal was detected with the preimmune serum or with the *spaB* disruption mutant, confirming that the cross-reaction with SpaB was specific. Considering that membrane proteins (see below) migrate slightly differently on SDS-gels,



the estimated protein molecular mass of 115 kDa is consistent with the molecular mass of 120.5 kDa derived from the *spaB* sequence.

The *spaR* and *spaK* disruption mutants were also tested

SpaB



NisB



EpiB





FIG. 4. Hydrophobicity plots for SpaB of *B. subtilis*, NisB of *L. lactis* 6F3, and EpiB of *S. epidermidis* Tü 3298 (= DSM 3095). Positive numbers indicate hydrophobicity. aa, amino acids. The arrows indicate the hydrophobic region present in all three proteins.

kDa 1 2 3 4 5




FIG. 5. Immunoblot analysis of SpaB. Lanes 1 through 3, protein extracts of *spaR*, *spaK*, and *spaB* disruption mutants, respectively; lanes 4 and 5, wild-type protein extract.

for SpaB expression by immunoblotting. SpaB protein was observed in wild-type cells, whereas no SpaB protein was detected in *spaR* and *spaK* mutants. These results show that the previously described "two-component" regulatory system for subtilin biosynthesis (30) acts via *spaB* expression. In order to analyze the regulation of SpaB, SpaB expression was monitored during growth. Wild-type cells were grown on TY media, and after vesicle preparation SpaB expression was monitored by performing a Western blot analysis. As shown in Fig. 6b, the SpaB protein was first detected after 3.5 h. The intensity of the SpaB protein signal increased until the stationary phase was reached and then decreased after overnight incubation of stationary-phase cells.

The expression of the SpaB protein correlated strongly with subtilin biosynthesis, as shown by bioassay tests performed with *M. luteus* as the test organism. Severe growth inhibition was observed with wild-type cells after 5 h, which coincided with the detection of the SpaB protein (Fig. 6c). No growth inhibition occurred with the *spaB* disruption mutant (31). These results indicated that *spaB* is involved in subtilin biosynthesis and showed that *spaB* expression and subtilin biosynthesis are strongly related.

Preparation of *B. subtilis* vesicles and membrane localization of SpaB. After centrifugation, most of the cross-reacting activity was present in the sediment, indicating that SpaB was associated with the membrane. In order to establish the membrane localization, *B. subtilis* vesicles were prepared.

The proteins attached to the vesicles were analyzed by performing an immunoblot analysis. The 115-kDa SpaB protein was associated with the vesicle fraction and was released only after treatment with SDS (Fig. 7). After several resuspension steps followed by repeated centrifugation, the SpaB protein was still found in the vesicle fraction, and no depletion was observed. Even after vesicle disintegration by vigorous agitation with glass beads, SpaB was still in the membrane fraction. These results strongly suggest that SpaB is membrane bound and support our hypothesis that lantibiotic biosynthesis occurs at the cell membrane.

The integrity of the prepared vesicles was tested by using pyranine, which does not significantly bind to phospholipid vesicles because of its polyanionic character (11). Control






FIG. 6. Regulation of SpaB expression and subtilin biosynthesis. (a) Growth curve of *B. subtilis* ATCC 6633. The numbers next to the curve correspond to lane designations in panel b and to colony designations in panel c. (b) Immunoblot analysis of SpaB expression during growth. Lane 1, 3.5 h; lane 2, 4.5 h; lane 3, 5.5 h; lane 4, 6.5 h; lane 5, 7.5 h; lane 6, 8.5 h; lane 7, 24 h. The times are the amounts of time after batch culture inoculation. (c) Bioassay for subtilin production. The numbers 1 to 6 correspond to those in panels a and b; number 7 corresponds to supernatant from a culture that was grown overnight.




FIG. 7. Membrane localization of SpaB. Protein extracts were separated by SDS-gel electrophoresis and detected by Western blot analysis. Crude extracts (lane 1) were centrifuged at $48,000 \times g$ for 30 min at $4^\circ C$ (lane 2, supernatant; lane 3, pellet), and the resulting membrane fraction (pellet) was resuspended and centrifuged again under the same conditions (lane 4, supernatant; lane 5, vesicle fraction). The final vesicle fraction (pellet) was treated with SDS and analyzed after further centrifugation at $48,000 \times g$ for 30 min at $4^\circ C$ (lane 6, supernatant; lane 7, pellet).

vesicles were formed in the presence of pyranine. Vesicles with incorporated pyranine were separated from external pyranine by gel chromatography. The amount of pyranine incorporated into the vesicles was estimated after vesicles were lysed with Triton X-100 and fluorescence was measured at 450 nm. From these results a pyranine concentration of $2.6 \times 10^{-8} M$ was calculated. The vesicles remained stable in the absence of Triton X-100.

DISCUSSION

The genes involved in subtilin biosynthesis are organized in an operon-like structure (25, 31). Genes *spaC*, *spaT*, and *spaB* are located upstream of the structural gene, *spaS*. These genes play a major role in subtilin biosynthesis as gene disruptions of *spaC* and *spaB* resulted in subtilin-negative mutants (25, 31). The SpaT protein exhibited a high level of homology with ATP-binding cassette transport proteins. The initial gene disruption experiments identified a mutant that was capable of producing subtilin but had a clumpy phenotype and became nonviable at the growth phase at which subtilin biosynthesis began (25, 31). Additional experiments, however, revealed that this phenotype occurred only when kanamycin was used as a resistance marker for gene disruption. When the *cat* gene was used as a resistance marker, the resulting mutants were subtilin negative (30). These results showed that all three genes which are upstream of *spaS* that have been identified are necessary for subtilin biosynthesis. In this study we isolated the complete *spaB* gene and deduced that the open reading frame encodes a protein having 1,030 amino acids. Upstream from *spaB* a putative promoter that has similarities to vegetative sigma A promoters of *B. subtilis* (40) was identified. No additional open reading frames upstream from *spaB* on the DNA fragment that was isolated could be identified for the following 300 bp. As deduced from the *spaB* gene, a protein with a molecular mass of 1,250 kDa was expected. By using antibodies directed against SpaB, a protein having the expected molecular mass was detected by Western blot analysis. No cross-reactions were observed with the preimmune serum and

after a Western blot analysis of crude extracts from the *spaB* disruption mutants. These results cast doubt on the recent statement of Chung and Hansen (10) that the DNA sequence that we attribute to *spaB* may correspond to two genes, referred to by these authors as *spaD* and *spaE* (10).

The *spaB* gene described in this report was homologous to *epiB* (46, 47) and *nisB* (13), which have been shown to be involved in the biosynthesis of epidermin and nisin, respectively. These genes encode proteins having 1,030 (*spaB*), 990 (*epiB*), and 993 (*nisB*) amino acid residues and exhibit significant levels of homology over the entire sequence. Unfortunately, no functional domains, as indicated by strongly conserved stretches of homologous sequences, could be identified. A search for similarity between the SpaB, NisB, and EpiB proteins and threonine dehydratases revealed some similarity, which suggests that SpaB, NisB, and EpiB have a dehydratase function.

To understand the function of SpaB in subtilin biosynthesis, we used specific antibodies to investigate the cellular localization of the SpaB protein. The method of Konings et al. (34) was used for *B. subtilis* membrane preparation; vesicles were isolated, and the integrity of the isolated vesicles was proven with the dye pyranine, which does not interact with membranes (11). Our results showed that SpaB copurified with the vesicle fraction, which indicates that the SpaB protein is associated with the cellular membrane of *B. subtilis*. A similar result was found previously for NisB, which is associated with the cellular membrane of *L. lactis* (13). Surprisingly, SpaB, NisB, and EpiB are rather hydrophilic proteins. There is a hydrophobic region present in SpaB between amino acid residues 875 and 900 which may play a role in membrane integration. A similarly localized hydrophobic area is also present in EpiB between amino acids 830 and 860. For NisB a change from hydrophilic to hydrophobic character is also found between amino acid residues 825 and 850, but this change is less pronounced than the change in the other proteins. Perhaps this area is important for membrane attachment. Alternatively, if no regions for membrane integration are present on these proteins, they might attach to membranes by interactions with other proteins, such as the more hydrophobic SpaC, NisC, and EpiC proteins, indicating that there is a membrane-localized multifunctional protein complex for lantibiotic biosynthesis. This possibility is consistent with the ideas that modification reactions occur in the prepeptides and that the mature lantibiotic is released from the modified prepeptide by proteolytic cleavage during or after transport through the cytoplasmic membrane (49). Thus far, two observations confirm this hypothesis. First, a modified prepeptide was isolated with antibodies directed against the leader sequence of lantibiotic Pep5 (53), and second, a protease specific for cleavage of the nisin prepeptide was recently localized extracellularly (51).

We recently showed that subtilin biosynthesis is regulated by a so-called two-component regulatory system which is composed of a membrane-localized histidine kinase and a response regulator (30). A similar regulatory system was also identified for nisin biosynthesis by identifying the *nisR* gene encoding the putative response regulator (51). This indicates that the genes encoding the proteins involved in lantibiotic biosynthesis could be the target for this regulatory system. Indeed, we showed that *spaB* is not expressed in *spaR* and *spaK* gene disruption mutants. In addition, we monitored subtilin production and *spaB* expression in a batch culture experiment. Our results clearly revealed that *spaB* expres-

sion strongly coincided with subtilin production, indicating that *spaB* plays a major role in subtilin biosynthesis.

ACKNOWLEDGMENTS

We thank A. Kröger and V. Geisler for advice on using the pyranine system and G. Engelke, P. Kiesau, and A. Brüning for stimulating discussions.

This work was supported by SFB 169 from the Deutsche Forschungsgemeinschaft. Z. Gutowski-Eckel received a Liebig grant from the Fonds der Chemischen Industrie, and C. Klein also received a grant from the Fonds der Chemischen Industrie.

REFERENCES

- Allgaier, H., G. Jung, R. G. Werner, U. Schneider, and H. Zähner. 1985. Elucidation of the structure of epidermin, a ribosomally synthesized tetracyclic heterodetic polypeptide antibiotic. *Angew. Chem. Int. Ed. Engl.* **24**:1051-1053.
- Allgaier, H., G. Jung, R. G. Werner, U. Schneider, and H. Zähner. 1986. Epidermin: sequencing of a heterodetic tetracyclic 21-peptide amide antibiotic. *Eur. J. Biochem.* **160**:9-22.
- Augustin, J., R. Rosenstein, T. Kupke, U. Schneider, N. Schnell, G. Engelke, K.-D. Entian, and F. Götz. 1991. Identification of epidermin biosynthetic genes by complementation studies and heterologous expression, p. 277-286. *In* G. Jung and H.-G. Sahl (ed.), *Nisin and novel lantibiotics*. ESCOM Science Publishers, Leiden, The Netherlands.
- Augustin, J., R. Rosenstein, B. Wieland, U. Schneider, N. Schnell, G. Engelke, K.-D. Entian, and F. Götz. 1992. Genetic analysis of epidermin biosynthetic genes and epidermin-negative mutants of *Staphylococcus epidermidis*. *Eur. J. Biochem.* **204**:1149-1154.
- Banerjee, S., and J. N. Hansen. 1988. Structure and expression of a gene encoding the precursor of subtilin, a small protein antibiotic. *J. Biol. Chem.* **263**:9508-9514.
- Benedict, R. G., W. Dwonch, O. L. Shotwell, T. G. Pridham, and L. A. Lindenfesler. 1952. Cinnamycin, an antibiotic from *Streptomyces cinnamoneus* nov. spec. *Antibiot. Chemother. (Washington, D.C.)* **2**:591-594.
- Birnboim, H. C., and J. Doly. 1979. A rapid alkaline extraction procedure for screening recombinant plasmid DNA. *Nucleic Acids Res.* **7**:1513-1518.
- Buchmann, G. W., S. Banerjee, and J. N. Hansen. 1988. Structure, expression and evolution of a gene encoding the precursor of nisin, a small protein antibiotic. *J. Biol. Chem.* **263**:16260-16266.
- Chou, P. Y., and G. D. Fasman. 1978. Empirical predictions of protein conformation. *Annu. Rev. Biochem.* **47**:251-276.
- Chung, Y. J., and J. N. Hansen. 1992. Determination of the sequence of *spaE* and identification of a promoter in the subtilin (*spa*) operon in *Bacillus subtilis*. *J. Bacteriol.* **174**:6699-6702.
- Clement, N. R., and J. M. Gould. 1981. Pyranine (8-hydroxy-1,3,6-pyrenetrisulfonate) as a probe of internal aqueous hydrogen ion concentration in phospholipid vesicles. *Biochemistry* **20**:1534-1538.
- Dodd, H. M., N. Horn, and M. J. Gasson. 1990. Analysis of the genetic determinant for production of the peptide antibiotic nisin. *J. Gen. Microbiol.* **136**:555-566.
- Engelke, G., Z. Gutowski-Eckel, M. Hammelmann, and K. D. Entian. 1992. Biosynthesis of the lantibiotic nisin: genomic organization and membrane localization of the NisB protein. *Appl. Environ. Microbiol.* **58**:3730-3743.
- Fredenhagen, A., G. Fendrich, F. Märki, W. Märki, J. Gruner, F. Raschdorf, and H. H. Peter. 1990. Duramycin B and C, two new lanthionine containing antibiotics as inhibitor of phospholipase A2. *J. Antibiot.* **43**:1403-1412.
- Ganguli, B. N. 1989. Mersacidin, a novel peptide antibiotic. *Program Abstr. 29th Intersci. Conf. Antimicrob. Agents Chemother.*, abstr. 413.
- Gross, E., and J. H. Brown. 1976. *In* A. Loffet (ed.), *Peptides 1976*, p. 183-190. Editions de l'Université de Bruxelles, Brussels.
- Gross, E., and H. Kiltz. 1973. The number and nature of

- α,β -unsaturated amino acids in subtilin. *Biochem. Biophys. Res. Commun.* **50**:559–565.
18. Hancock, K., and V. C. W. Tsang. 1983. India ink staining of proteins on nitrocellulose paper. *Anal. Biochem.* **133**:157–162.
 19. Ingram, L. 1969. Synthesis of the antibiotic nisin: formation of lanthionine and β -methyl-lanthionine. *Biochim. Biophys. Acta* **184**:216–219.
 20. Ingram, L. 1970. A ribosomal mechanism for synthesis of peptides related to nisin. *Biochim. Biophys. Acta* **224**:263–265.
 21. Jung, G. 1991. Lantibiotics: a survey, p. 1–34. *In* G. Jung and H.-G. Sahl (ed.), *Nisin and novel lantibiotics*. ESCOM Science Publishers, Leiden, The Netherlands.
 22. Kaletta, C., and K.-D. Entian. 1989. Nisin, a peptide antibiotic: cloning and sequencing of the *nisA* gene and posttranslational processing of its peptide product. *J. Bacteriol.* **171**:1597–1601.
 23. Kaletta, C., K.-D. Entian, and G. Jung. 1991. Prepeptide sequence of Ro 09-0198: the first structural gene of a duramycin type lantibiotic. *Eur. J. Biochem.* **199**:411–415.
 24. Kaletta, C., K.-D. Entian, R. Kellner, G. Jung, M. Reis, and H. G. Sahl. 1989. Pep5, a new lantibiotic: structural gene isolation and prepeptide sequence. *Arch. Microbiol.* **152**:16–19.
 25. Kaletta, C., C. Klein, N. Schnell, and K.-D. Entian. 1991. An operon-like structure of genes involved in subtilin biosynthesis, p. 309–319. *In* G. Jung and H.-G. Sahl (ed.), *Nisin and novel lantibiotics*. ESCOM Science Publishers, Leiden, The Netherlands.
 26. Kellner, R., G. Jung, T. Hörner, N. Schnell, K.-D. Entian, and F. Götz. 1988. Gallidermin: a new lanthionine containing polypeptide antibiotic. *Eur. J. Biochem.* **177**:53–59.
 27. Kessler, H., S. Steuernagel, D. Gillissen, and T. Kamiyama. 1987. Complete sequence determination and localisation of one imino and three sulfide bridges of the nonadecapeptide Ro09-0198 by homonuclear 2D-NMR spectroscopy. The DQF-RELAYED-NOESY experiment. *Helv. Chim. Acta* **70**:726–741.
 28. Kessler, H., S. Steuernagel, M. Will, G. Jung, and R. Kellner. 1988. The structure of the polycyclic nonadecapeptide Ro09-0198. *Helv. Chim. Acta* **71**:1924–1929.
 29. Kim, S. S., and P. Datta. 1982. Chemical characterization of biodegradative threonine dehydratases from two enteric bacteria. *Biochim. Biophys. Acta* **706**:27–35.
 30. Klein, C., C. Kaletta, and K. D. Entian. 1993. Biosynthesis of the lantibiotic subtilin is regulated by a histidine kinase/response regulator system. *Appl. Environ. Microbiol.* **59**:296–303.
 31. Klein, C., C. Kaletta, N. Schnell, and K. D. Entian. 1992. Analysis of genes involved in biosynthesis of the lantibiotic subtilin. *Appl. Environ. Microbiol.* **58**:132–142.
 32. Koerner, T. J., J. E. Hill, A. M. Myers, and A. Tzagoloff. 1991. High-expression vectors with multiple cloning sites for construction of a *trpE* fusion gene: pATH vectors. *Methods Enzymol.* **194**:477–490.
 33. Kogler, H., M. Bauch, H. W. Fehlhaber, C. Griesinger, W. Schubert, and V. Teetz. 1991. NMR-spectroscopic investigations on mersacidin, p. 159–170. *In* G. Jung and H.-G. Sahl (ed.), *Nisin and novel lantibiotics*. ESCOM Science Publishers, Leiden, The Netherlands.
 34. Konings, W. N., A. Bisshop, M. Veenhuis, and C. A. Vermeulen. 1973. New procedure for isolation of membrane vesicles of *Bacillus subtilis* and an electron microscopy study of their ultrastructure. *J. Bacteriol.* **116**:1456–1465.
 35. Kyte, J., and R. F. Doolittle. 1982. A simple method for displaying the hydrophathic character of proteins. *J. Mol. Biol.* **157**:105–132.
 36. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature (London)* **227**:680–685.
 37. Lawther, R. P., R. C. Wek, J. M. Lopes, R. Pereira, B. E. Taillon, and G. W. Hatfield. 1987. The complete nucleotide sequence of the *ilvGMEDA* operon of *E. coli* K-12. *Nucleic Acids Res.* **15**:2137–2155.
 38. Mattick, A. T. R., and A. Hirsch. 1944. A powerful inhibitory substance produced by group N streptococci. *Nature (London)* **154**:551.
 39. Mattick, A. T. R., and A. Hirsch. 1947. Further observation on an inhibitory substance (nisin) from lactic streptococci. *Lancet* **ii**:5–12.
 40. Moran, C. P., Jr. 1990. Expression of sigma A and sigma H regulons during stationary phase and endospore formation, p. 287–294. *In* M. M. Zukowski, A. T. Ganesam, and J. A. Hoch (ed.), *Genetics and biotechnology of bacilli*, vol. 3. Academic Press, Inc., San Diego, Calif.
 41. Naruse, N., O. Tenmyo, K. Tomita, M. Konishi, T. Myaki, and H. Kawaguchi. 1989. Lanthiopeptin, a new peptide antibiotic. *J. Antibiot.* **62**:837–845.
 42. Rayman, K., and A. Hurst. 1984. Nisin: properties, biosynthesis and fermentation, p. 607–628. *In* E. J. Vandamme (ed.), *Biotechnology of industrial antibiotics*. Marcel Dekker, New York.
 43. Sahl, H. G., and H. Brandis. 1981. Production, purification and chemical properties of an antistaphylococcal agent produced by *Staphylococcus epidermidis*. *J. Gen. Microbiol.* **127**:377–384.
 44. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. *Molecular cloning: a laboratory manual*, 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
 45. Sanger, F., S. Nicklen, and A. R. Coulson. 1977. DNA sequencing with chain-terminating inhibitors. *Proc. Natl. Acad. Sci. USA* **74**:5463–5467.
 46. Schnell, N., G. Engelke, J. Augustin, R. Rosenstein, F. Götz, and K.-D. Entian. 1991. The operon-like organisation of lantibiotic epidermin biosynthesis genes, p. 269–276. *In* G. Jung and H.-G. Sahl (ed.), *Nisin and novel lantibiotics*. ESCOM Science Publishers, Leiden, The Netherlands.
 47. Schnell, N., G. Engelke, J. Augustin, R. Rosenstein, V. Ungermann, F. Götz, and K.-D. Entian. 1992. Analysis of genes involved in the biosynthesis of lantibiotic epidermin. *Eur. J. Biochem.* **204**:57–68.
 48. Schnell, N., K.-D. Entian, F. Götz, T. Hörner, R. Kellner, and G. Jung. 1989. Structural gene isolation and prepeptide sequence of gallidermin, a new lanthionine containing antibiotic. *FEMS Microbiol. Lett.* **58**:263–268.
 49. Schnell, N., K.-D. Entian, U. Schneider, F. Götz, H. Zähner, R. Kellner, and G. Jung. 1988. Prepeptide sequence of epidermin, a ribosomally synthesized antibiotic with four sulphide-rings. *Nature (London)* **333**:276–278.
 50. Tautz, D., and N. Renz. 1983. An optimized freeze squeeze method for the recovery of DNA fragments from agarose gels. *Anal. Biochem.* **132**:503–517.
 51. van der Meer, J. R., J. Polman, M. M. Beerthuyzen, R. J. Siezen, O. P. Kuipers, and W. M. de Vos. 1993. Characterization of the *Lactococcus lactis* nisin A operon genes *nisP*, encoding a subtilisin-like serine protease involved in precursor processing, and *nisR*, encoding a regulatory protein involved in nisin biosynthesis. *J. Bacteriol.* **175**:2578–2588.
 52. Wakamiya, T., Y. Ueki, T. Shiba, Y. Kido, and Y. Motoki. 1985. The structure of ancovenin, a new peptide inhibitor of angiotensin I converting enzyme. *Tetrahedron Lett.* **26**:665–668.
 53. Weil, H.-P., A. G. Beck-Sickinger, J. Metzger, S. Stevanovic, G. Jung, M. Josten, and H.-G. Sahl. 1990. Biosynthesis of the lantibiotic Pep5. Isolation and characterization of a prepeptide containing dehydroamino acids. *Eur. J. Biochem.* **194**:217–223.
 54. Zamenhoff, S. 1957. Preparation and assay of desoxyribonucleic acids from animal tissue. *Methods Enzymol.* **3**:696–704.